AF
INKT icon

Amalgamated Financial’s MiNK Therapeutics INKT Stock Holding History

Amalgamated Financial’s Portfolio INKT Stock Details INKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$1K Buy
+30
New +$901 ﹤0.01% 2991

Other funds holding INKT

SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Amalgamated Financial's INKT Position: Q1 2022 in Review

Amalgamated Financial opened a new position in MiNK Therapeutics (INKT) in Q1 2022: 30 shares worth $1K. The stake represents ﹤0.01% of the portfolio and ranks #2991 among its holdings.

25 funds tracked by Wall St. Rank hold INKT as of Q1 2022.

  • Amalgamated Financial held 30 shares of MiNK Therapeutics worth $1K as of Q1 2022.
  • MiNK Therapeutics was a new Amalgamated Financial position in Q1 2022.
  • MiNK Therapeutics made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2991 holding.
  • 25 funds tracked by Wall St. Rank held MiNK Therapeutics as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.